In multiple experimental LM models, melittin nanoparticles have been demonstrated to induce the activation of LSECs to reverse the hepatic immunological environment to the activated state, which recruits NK and CD8+ T cells and suppresses LM [90]. The gene discussed is CD8A; the disease is lymphangioma.